# Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage

Study · id `cardio:ct-nct07249853` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07249853](<https://clinicaltrials.gov/study/NCT07249853>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07249853

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 380 participants.

## Technical summary

Registry record NCT07249853. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-06 (actual); primary completion 2027-05-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 380 participants (planned count; ClinicalTrials.gov record NCT07249853, source copy `cardio:ctgov-nct07249853-2026-10-16`, retrieved 2026-10-31)
- Started: 2025-12-06 (actual) (ClinicalTrials.gov record NCT07249853, source copy `cardio:ctgov-nct07249853-2026-10-16`, retrieved 2026-10-31)
- Primary completion: 2027-05-31 (anticipated) (ClinicalTrials.gov record NCT07249853, source copy `cardio:ctgov-nct07249853-2026-10-16`, retrieved 2026-10-31)
- Completion: 2027-08-31 (anticipated) (ClinicalTrials.gov record NCT07249853, source copy `cardio:ctgov-nct07249853-2026-10-16`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07249853, source copy `cardio:ctgov-nct07249853-2026-10-16`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07249853-2026-10-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage
- Acronym: CAPTAIN
- Condition: Aneurysmal Subarachnoid Hemorrhage
- Intervention (Drug): Cilostazol 100 mg BID
- Intervention (Drug): placebo
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Subarachnoid hemorrhage (`cardio:subarachnoid-hemorrhage`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)

## Provenance

Content hash: 042304700628d7705458abca74e2c33a7f937e3df7ceac861e760a6d29b28da0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
